Results 211 to 220 of about 324,101 (292)

How to Define and Manage Low-Risk Drug Allergy Labels. [PDF]

open access: yesJ Allergy Clin Immunol Pract
Copaescu AM   +3 more
europepmc   +1 more source

Long‐Term Quality of Life in 1777 Persons With Hodgkin Lymphoma and 6166 Matched Comparators

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Survival has improved substantially for patients with Hodgkin lymphoma (HL), but long‐term quality of life (QoL) remains incompletely understood. This was a Danish, nationwide, cross‐sectional study of QoL among persons with a diagnosis of HL matched 1:10 to general population comparators.
Sissel Johanne Godtfredsen   +13 more
wiley   +1 more source

Recurrent Genomic Alterations in BCRi‐Experienced CLL Patients Treated With Venetoclax: Extended Phase 2 Follow‐Up

open access: yes
American Journal of Hematology, EarlyView.
Jennifer A. Woyach   +16 more
wiley   +1 more source

Real‐World Outcomes of FLAG‐Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT In a large multicenter real‐world cohort, we aimed to evaluate outcomes of FLAG‐Ida salvage therapy for relapsed/refractory (R/R) acute myeloid leukemia (AML) and validated the SALFLAGE prognostic score. We analyzed 1079 adults with R/R AML treated across 112 PETHEMA institutions over 26 years (1998–2024), including patients with primary ...
Gaspar Aspas Requena   +49 more
wiley   +1 more source

Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Graft versus host disease (GVHD) prophylaxis with posttransplant cyclophosphamide (ptCY) and cytomegalovirus (CMV) prophylaxis with letermovir have changed the clinical epidemiology of CMV infection. We studied the incidence, risk factors for, and outcomes of CMV infection after Day + 90 of allogeneic hematopoietic cell transplant (alloHCT ...
George L. Chen   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy